Oral Presentation on Bio-Hermes to Take Place at Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD)
Washington D.C., Mar 04, 2024- Global Alzheimer’s Platform Foundation®, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by Douglas Beauregard, Project Director of Clinical Operations at Global Alzheimer’s Platform Foundation at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (ADPD). The oral presentation will take place on Friday, March 8 during the conference which will be held in Lisbon, Portugal and virtually from March 5 to March 9, 2024.
Oral Presentation: Bio-Hermes: A study to Assess the Relationship of Blood Biomarkers with AB Pet Scans and the Differences Between Ethnic/Racial Relationships
In the Symposium on Fluid Biomarkers and Imaging on Friday, March 8 at 1:40 pm EST, Douglas Beauregard will present the latest data from the GAP-sponsored blood-based and digital biomarker study, Bio-Hermes. Bio-Hermes is a head-to-head study comparing several blood-based biomarkers and digital tests to evaluate their ability to improve Alzheimer’s disease detection and diagnosis compared to amyloid PET scans. The presentation will include the analysis of the relationship between these tests to enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s Disease. The presentation will also include data that reflects diverse populations at risk for Alzheimer’s disease.
“It is an honor to have the opportunity for presenting Bio-Hermes at ADPD. Bio-Hermes is monumental in providing head-to-head comparisons of data available from many leading Alzheimer’s diagnostic tests today and has resulted in a rich dataset to reduce the historical barriers to access and timely diagnosis and care. We are grateful for the opportunity to highlight our contributions to the field which impacts our collective goal of accelerating treatments for Alzheimer’s disease and ultimately finding a cure,” said GAP Project Director of Clinical Operations, Douglas Beauregard.
Date and time: Friday, March 8; 1:40 pm- 2:40 pm EST
- Presented by: Douglas Beauregard, Project Director, Clinical Operations, Global Alzheimer’s Platform Foundation
For more information on GAP, visit https://globalalzplatform.org/.
—END—
About GAP
The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).